MARKET

ATRI

ATRI

Atrion Corp
NASDAQ
402.35
+16.65
+4.32%
After Hours: 402.35 0 0.00% 16:02 04/19 EDT
OPEN
383.00
PREV CLOSE
385.70
HIGH
408.00
LOW
381.31
VOLUME
38.77K
TURNOVER
0
52 WEEK HIGH
670.00
52 WEEK LOW
271.54
MARKET CAP
708.12M
P/E (TTM)
36.50
1D
5D
1M
3M
1Y
5Y
Positive Signs As Multiple Insiders Buy Atrion Stock
Atrion Corporation's (NASDAQ:ATRI) insider trading is good news for shareholders. In the last year Atrion insiders bought US$105k worth of shares at a price of US$409. The company has had no insider transactions in the last three months. At rion insiders own 16% of the company. It's a good sign to see an insider buy up shares at higher prices. But we warn you to be aware of the risks associated with atrion. You can see the insider transactions of Atrions over the last 12 months.
Simply Wall St · 2d ago
Weekly Report: what happened at ATRI last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at ATRI last week (0401-0405)?
Weekly Report · 04/08 09:28
Weekly Report: what happened at ATRI last week (0325-0329)?
Weekly Report · 04/01 09:28
Weekly Report: what happened at ATRI last week (0318-0322)?
Weekly Report · 03/25 09:28
Dividend Champion, Contender, And Challenger Highlights: Week Of March 24
Home Dividends Analysis Dividend Quick Picks: Week of March 24. Justin Law's weekly summary of dividend activity for D dividend Champions, Contenders, and Challengers. This week, he highlights recent and upcoming dividend related activity for dividend stocks on the D dividend champions list.
Seeking Alpha · 03/24 12:37
Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading
Atrion Corporation is a healthcare company focused on fluid delivery products. The company has experienced a decline in revenue, profits, and cash flows. The stock is currently expensive compared to similar companies. Despite the potential for improvement in the future, the company is overvalued. Atrion has been downgraded to a 'sell' rating.
Seeking Alpha · 03/24 12:34
Subdued Growth No Barrier To Atrion Corporation (NASDAQ:ATRI) With Shares Advancing 25%
Atrion Corporation (NASDAQ:ATRI) has posted a 25% gain in the last month. The company's share price is still down 34% over the last year. Atrion has a 38.6x price-to-earnings ratio and is trading at a much higher than average P/E ratio. Its recent earnings have been in decline over the medium-term, and the company is expected to perform better than the market.
Simply Wall St · 03/23 12:11
More
About ATRI
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.

Webull offers Atrion Corp stock information, including NASDAQ: ATRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRI stock methods without spending real money on the virtual paper trading platform.